AI Engines For more Details: Perplexity Kagi Labs You
Bronchodilation: Diprophylline works by relaxing the smooth muscles in the airways of the lungs, leading to bronchodilation. This helps to widen the airways and improve airflow, making it easier to breathe. It is particularly useful in the management of asthma and COPD, where bronchoconstriction contributes to symptoms such as wheezing, shortness of breath, and coughing.
Asthma: Diprophylline may be used as a maintenance therapy to help control asthma symptoms and prevent asthma attacks. It is often prescribed in combination with other asthma medications, such as inhaled corticosteroids and short-acting bronchodilators, to achieve optimal asthma control.
Chronic Obstructive Pulmonary Disease (COPD): Diprophylline can also be used in the management of COPD, a progressive lung disease characterized by airflow limitation and breathing difficulties. By dilating the airways, diprophylline helps relieve symptoms such as shortness of breath, coughing, and wheezing in individuals with COPD.
Chronic Bronchitis: Diprophylline may be prescribed to individuals with chronic bronchitis, a type of COPD characterized by inflammation of the bronchial tubes and excessive mucus production. By promoting bronchodilation, diprophylline can help alleviate symptoms and improve lung function in individuals with chronic bronchitis.
Emphysema: In some cases, diprophylline may be used as part of the treatment regimen for emphysema, another form of COPD characterized by damage to the air sacs in the lungs. While diprophylline can help improve airflow in individuals with emphysema, it is typically used in conjunction with other therapies, such as supplemental oxygen and pulmonary rehabilitation.
Respiratory Distress in Premature Infants: Diprophylline may also be used in the treatment of respiratory distress syndrome (RDS) in premature infants. By promoting bronchodilation and improving lung function, diprophylline can help alleviate breathing difficulties in newborns with RDS.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 2.6 | 0.3 | 7.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2 | 1 | 1 |
| Allergies | 2.3 | 0.8 | 1.87 |
| Allergy to milk products | 0.3 | 1 | -2.33 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 2 | 3.1 | -0.55 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 1.3 | |
| Ankylosing spondylitis | 2.6 | 0.6 | 3.33 |
| Anorexia Nervosa | 1.1 | 2.1 | -0.91 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 3.8 | 1.9 | 1 |
| Atherosclerosis | 0.6 | 0.7 | -0.17 |
| Atrial fibrillation | 2.9 | 1.2 | 1.42 |
| Autism | 4 | 4.7 | -0.18 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1 | 1.1 | -0.1 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Cancer (General) | 0.6 | 0.8 | -0.33 |
| Carcinoma | 2.6 | 2 | 0.3 |
| Celiac Disease | 1.2 | 2.9 | -1.42 |
| Cerebral Palsy | 1.2 | 1 | 0.2 |
| Chronic Fatigue Syndrome | 2.2 | 3.1 | -0.41 |
| Chronic Kidney Disease | 1.9 | 1 | 0.9 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 1.4 | -1 |
| Chronic Urticaria (Hives) | 0.6 | 0.6 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 2.9 | 1.4 | 1.07 |
| Colorectal Cancer | 2.4 | 1.4 | 0.71 |
| Constipation | 0.6 | 0.7 | -0.17 |
| Coronary artery disease | 0.6 | 1.7 | -1.83 |
| COVID-19 | 3.9 | 4.3 | -0.1 |
| Crohn's Disease | 3.9 | 3.2 | 0.22 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.4 | -1.4 | |
| deep vein thrombosis | 0.7 | 1.1 | -0.57 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 5 | 4.1 | 0.22 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.6 | 0.9 | -0.5 |
| Endometriosis | 2 | 1.4 | 0.43 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1 | 1.1 | -0.1 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 2.5 | 0.6 | 3.17 |
| Functional constipation / chronic idiopathic constipation | 2.2 | 1.7 | 0.29 |
| gallstone disease (gsd) | 1.4 | 0.8 | 0.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 1.1 | -2.67 |
| Generalized anxiety disorder | 1 | 1.2 | -0.2 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.8 | 0.8 | |
| Graves' disease | 1.3 | 2.4 | -0.85 |
| Gulf War Syndrome | 0.4 | 0.3 | 0.33 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.1 | 0.9 | 1.33 |
| Heart Failure | 1.2 | 1.1 | 0.09 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.3 | 1.1 | -2.67 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 2.3 | 2.7 | -0.17 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.6 | 0.3 | 4.33 |
| IgA nephropathy (IgAN) | 1.3 | 1.4 | -0.08 |
| Inflammatory Bowel Disease | 2.8 | 4.3 | -0.54 |
| Insomnia | 1.7 | 2.1 | -0.24 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.9 | 0.9 | |
| Irritable Bowel Syndrome | 2.6 | 2.4 | 0.08 |
| ischemic stroke | 2 | 1.1 | 0.82 |
| Liver Cirrhosis | 4.2 | 2.3 | 0.83 |
| Long COVID | 3.4 | 4.3 | -0.26 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0 | 0.7 | 0 |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.6 | 1.1 | -0.83 |
| ME/CFS without IBS | 0.9 | 1.6 | -0.78 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.8 | 0.5 | 0.6 |
| Metabolic Syndrome | 3.1 | 4.2 | -0.35 |
| Mood Disorders | 4.5 | 3.6 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 2.8 | 2.8 | 0 |
| Multiple system atrophy (MSA) | 0.2 | 0.4 | -1 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 2.3 | -6.67 |
| Neuropathy (all types) | 0.7 | 1.2 | -0.71 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 3 | -0.15 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 3.9 | 4.3 | -0.1 |
| obsessive-compulsive disorder | 2.1 | 2.2 | -0.05 |
| Osteoarthritis | 0.9 | 0.9 | 0 |
| Osteoporosis | 1.4 | 1.3 | 0.08 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.1 | 3.5 | -0.13 |
| Polycystic ovary syndrome | 2.9 | 1.8 | 0.61 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 1.2 | 0.3 | 3 |
| Primary sclerosing cholangitis | 1.5 | 1.5 | 0 |
| Psoriasis | 1 | 1.9 | -0.9 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.4 | 2.6 | 0.31 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 3.2 | 2.3 | 0.39 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 1.6 | 2.2 | -0.38 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.3 | 2 |
| Stress / posttraumatic stress disorder | 2.1 | 1.9 | 0.11 |
| Systemic Lupus Erythematosus | 2 | 1.7 | 0.18 |
| Tic Disorder | 0.6 | 0.9 | -0.5 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 1 | 2.5 | -1.5 |
| Type 2 Diabetes | 3.7 | 3.4 | 0.09 |
| Ulcerative colitis | 2.8 | 2 | 0.4 |
| Unhealthy Ageing | 2 | 1.7 | 0.18 |
| Vitiligo | 1.6 | 0.7 | 1.29 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
